Three recent randomized clinical trials have shown that 2 distinct oral medications can effectively lower plasma potassium levels in patients with hyperkalemia, a notoriously challenging but common problem in chronic kidney disease and heart failure. The drugs, which haven’t been approved by the US Food and Drug Administration, have different mechanisms of action. Patiromer binds potassium, primarily in the colon. Sodium zirconium cyclosilicate is a highly selective cation exchanger that traps potassium in the intestines.
Slomski A. Hyperkalemia Controlled With 2 Novel Medications. JAMA. 2015;313(4):347. doi:10.1001/jama.2014.18441
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: